Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period

Acta Anaesthesiologica Scandinavica

Volumn 49, Issue 1, 2005, Pages 78-84

  Beilin, Benzion ^a   Bessler, H ^a,b   Papismedov, L ^a   Weinstock, M ^c   Shavit, Y ^d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Morphine consumption; Physostigmine; Postoperative pain; Proinflammatory cytokines

Indexed keywords

ACETYLCHOLINE; CYTOKINE; FENTANYL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LORAZEPAM; MIDAZOLAM; MORPHINE; NEOSTIGMINE; NITROUS OXIDE; ONDANSETRON; OPIATE; PHYSOSTIGMINE; PROPOFOL; VECURONIUM;

ACETYLCHOLINE BRAIN LEVEL; ADULT; AGED; ANESTHESIA INDUCTION; ANESTHESIA MECHANISM; ANESTHESIOLOGICAL TECHNIQUES; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INFUSION; DRUG RESPONSE; DRUG USE; EX VIVO STUDY; HUMAN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE ANALGESIA; POSTOPERATIVE NAUSEA; POSTOPERATIVE PAIN; POSTOPERATIVE VOMITING; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL ANALOG SCALE;

ADULT; AGED; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; IMMUNOASSAY; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MIDDLE AGED; MORPHINE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PHYSOSTIGMINE; POSTOPERATIVE NAUSEA AND VOMITING;

EID: 13444282541     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2004.00548.x     Document Type: Article

References (39)

1. Kehlet H, Werner M, Perkins F. Balanced analgesia: what is it and what are its advantages in postoperative pain? Drugs 1999; 58: 793-7.
2. Nemirovsky A, Niv D. Cholinergic mechanisms and antinociception. In: Raj P, Aronoff G, Pawl R, Parris W, eds. Current Review of Pain. Current Science. Current Medicine, Philadelphia, 1994: 10-22.
3. Hartvig P, Gillberg PG, Gordh T Jr, Post C. Cholinergic mechanisms in pain and analgesia. Trends Pharmacol Sci (suppl) 1989; 10: 75-9.
4. Hallak M, Giacobini E. Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat. Neurochem Res 1986; 11: 1037-48.
5. Nilsson L, Nordberg A, Hardy J, Wester P, Winblad B. Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level. J Neural Transm 1986; 67: 275-85.
6. Romano JA, Shih TM. Cholinergic mechanisms of analgesia produced by physostigmine, morphine and cold water swimming. Neuropharmacology 1983; 22: 827-33.
7. Yaksh TL, Dirksen R, Harty GJ. Antinociceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol 1985; 117: 81-8.
8. Petersson J, Gordh TE, Hartvig P, Wiklund L. A double-blind trial of the analgesic properties of physostigmine in postoperative patients. Acta Anaesthesiol Scand 1986; 30: 283-8.
9. Weinstock M, Davidson JT, Rosin AJ, Schnieden H. Effect of physostigmine on morphine-induced postoperative pain and somnolence. Br J Anaesth 1982; 54: 429-34.
10. Snir-Mor I, Weinstock M, Davidson JT, Bahar M. Physostigmine antagonizes morphine-induced respiratory depression in human subjects. Anesthesiology 1983; 59: 6-9.
11. Schneck HJ, Rupreht J. Central anticholinergic syndrome (CAS) in anesthesia and intensive care. Acta Anaesthesiol Belg 1989; 40: 219-28.
12. Furey ML, Pietrini P, Alexander GE et al. Time course of pharmacodynamic and pharmacokinetic effects of physostigmine assessed by functional brain imaging in humans. Pharmacol Biochem Behav 2000; 66: 475-81.
13. Salo M. Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand 1992; 36: 201-20.
14. Beilin B, Bessler H, Mayburd E et al. Effects of preemptive analgesia on pain and cytokine production in the postoperative period. Anesthesiology 2003; 98: 151-5.
15. Beilin B, Shavit Y, Trabekin E et al. The effects of postoperative pain management on immune response to surgery. Anesth Analg 2003; 97: 822-7.
16. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
17. Kim SI, Han TH, Kil HY, Lee JS, Kim SC. Prevention of postoperative nausea and vomiting by continuous infusion of subhypnotic propofol in female patients receiving intravenous patient-controlled analgesia. Br J Anaesth 2000; 85: 898-900.
18. Sadhasivam S, Saxena A, Kathirvel S, Kannan TR, Trikha A, Mohan V. The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. Anesth Analg 1999; 89: 1340-5.
19. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993; 52: 441-8.
20. Duttaroy A, Gomeza J, Gan JW et al. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 2002; 62: 1084-93.
21. Gage HD, Gage JC, Tobin JR et al. Morphine-induced spinal cholinergic activation: in vivo imaging with positron emission tomography. Pain 2001; 91: 139-45.
22. Chen SR, Pan HL. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats. Anesthesiology 2001; 95: 525-30.
23. Kushida K, Ishida K, Kikuta J, Kato M, Uchiyama T, Taguchi K. Alpha 2-adrenoceptor modulates the release of acetylcholine from the rostral ventrolateral medulla in response to morphine. Biol Pharm Bull 2003; 26: 1548-51.
24. Gillberg PG, Hartvig P, Gordh T et al. Behavioral effects after intrathecal administration of cholinergic receptor agonists in the rat. Psychopharmacology (Berl) 1990; 100: 464-9.
25. Widman M, Rosin D, Dewey WL. Effects of divalent cations, lanthanum, cation chelators and an ionophore on acetylcholine antinociception. J Pharmacol Exp Ther 1978; 205: 311-8.
26. Beilin B, Nemirovsky AY, Zeidel A, Maibord E, Zelman V, Katz RL. Systemic physostigmine increases the antinociceptive effect of spinal morphine. Pain 1997; 70: 217-21.
27. Abram SE, Winne RP. Intrathecal acetyl cholinesterase inhibitors produce analgesia that is synergistic with morphine and clonidine in rats. Anesth Analg 1995; 81: 501-7.
28. Patil CS, Kulkarni SK. The morphine sparing effect of physostigmine. Meth Find Exp Clin Pharmacol 1999; 21: 523-7.
29. Hartvig P, Wiklund L, Lindstrom B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol Scand 1986; 30: 177-82.
30. Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A. Phenserine and ring C hetero-analogues. drug candidates for the treatment of Alzheimer's disease. Med Res Rev 1995; 15: 3-31.
31. Berkenbosch A, Olievier CN, Wolsink JG, DeGoede J, Rupreht J. Effects of morphine and physostigmine on the ventilatory response to carbon dioxide. Anesthesiology 1994; 80: 1303-10.
32. Hedner J, Kraiczi H, Peker Y, Murphy P. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med 2003; 168: 1246-51.
33. Hartvig P, Lindstrom B, Pettersson E, Wiklund L. Reversal of postoperative somnolence using a two-rate infusion of physostigmine. Acta Anaesthesiol Scand 1989; 33: 681-5.
34. Ries CR. Physostigmine in 1999: tolerability, indications and availability. Can J Anaesth 1999; 46: 707.
35. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-9.
36. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988; 334: 698-700.
37. Oka T, Oka K, Hosoi M, Aou S, Hori T. The opposing effects of interleukin-1 beta microinjected into the preoptic hypothalamus and the ventromedial hypothalamus on nociceptive behavior in rats. Brain Res 1995; 700: 271-8.
38. Watkins LR, Maier SF, Goehler LE. Immune activation. the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995; 63: 289-302.
39. Wolf G, Yirmiya R, Goshen I et al. Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain 2003; 104: 471-80.